Evaluating New Breast Cancer Treatments
Phase 1/2
792
about 13 years
18+
16 sites in CA, CO, FL +5
About this study
Researchers are testing multiple treatment combinations in people with advanced or locally advanced breast cancer. The trial will be done in two stages, starting with a group of participants who have never received immunotherapy and then including those who have progressed on previous treatments. Participants may receive different treatment combinations during the second stage if they experience disease progression.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Abemaciclib
- 2.Take Atezolizumab
- 3.Take Atirmociclib
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
abemaciclib, atezolizumab, cdk inhibitor, bevacizumab, capecitabine, carboplatin, empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine), eribulin
oral (Oral Tablet), injection (Injection), infusion, injection, oral, oral (Oral Capsule)
Primary: Objective Response Rate (ORR)
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), Overall Survival (at specific time-points), Percentage of Participants with Adverse Events, Progression Free Survival (PFS)
Oncology